Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Montelukast. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 known ✓ | Q9Y271 | 6/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 5/20 | 1.00 |
| ▸ | CYP2C8 | P10632 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | FPR1 | P21462 | 1/20 | 1.00 |
| ▸ | GPR183 | P32249 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 0.87 |
| ▸ | RECQL | P46063 | 1/20 | 0.87 |
| ▸ | BLM | P54132 | 1/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.87 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.87 |
| ▸ | EGFR | P00533 | 1/20 | 0.87 |
| ▸ | ESR1 | P03372 | 1/20 | 0.87 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.87 |
| ▸ | FYN | P06241 | 1/20 | 0.87 |
| ▸ | PGR | P06401 | 1/20 | 0.87 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.87 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.87 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.87 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Montelukast SCHEMBL31425566 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL9414 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL5267922 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL29840730 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL29573125 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL3229836 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL29369947 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL4788140 | 1.00 | CYSLTR1 (1.00) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL8533560 | 0.99 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 | |
| Montelukast SCHEMBL6381434 | 0.99 | CYSLTR1 (0.99) | CYSLTR1CYSLTR2CYP2C8CYP2C9FPR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 7064 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025151851-A1 | BIOMARKERS OF ALLERGIC ASTHMA AND METHODS OF TREATMENT | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2025-07-17 | — | — | WO | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| WO-2023203306-A1 | COMPOSITIONS AND APPLICATIONS THEREOF | NASALEZE PATENTS LIMITED (IM) | 2023-10-26 | — | — | WO | claimed |
| EP-4259153-A1 | NOVEL USE OF PYRROLOPYRIDINE DERIVATIVES FOR PREVENTING OR TREATING INFLAMMATORY DISEASES | Voronoi Inc. (KR) | 2023-10-18 | — | — | EP | claimed |
| US-20220257605-A1 | NOVEL USE OF PYRROLOPYRIDINE DERIVATIVES FOR PREVENTING OR TREATING INFLAMMATORY DISEASES | VORONOI CO., LTD. (KR) | 2022-08-18 | — | — | US | claimed |
| WO-2022123311-A1 | NOVEL USE OF PYRROLOPYRIDINE DERIVATIVES FOR PREVENTING OR TREATING INFLAMMATORY DISEASES | VORONOI CO., LTD. (KR) | 2022-06-16 | — | — | WO | claimed |
| US-11004545-B2 | Clinical effect of pharmaceutical products using communication tool integrated with compound of several pharmaceutical products | INTELLECTUAL PROPERTY ENABLER STOCKHOLM AB (SE) | 2021-05-11 | — | — | US | claimed |
| US-20190122749-A1 | CLINICAL EFFECT OF PHARMACEUTICAL PRODUCTS USING COMMUNICATION TOOL INTEGRATED WITH COMPOUND OF SEVERAL PHARMACEUTICAL PRODUCTS | INTELLECTUAL PROPERTY ENABLER STOCKHOLM AB (SE) | 2019-04-25 | — | — | US | claimed |
| WO-2017161387-A1 | COMPOSITIONS OF NATURAL EXTRACTS AND USE THEREOF IN METHODS FOR PREVENTING OR TREATING DISEASES | REID CHRISTOPHER BRIAN (US) | 2017-09-21 | — | — | WO | claimed |
| CN-106456628-A | Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders | 无限药品股份有限公司 | 2017-02-22 | — | — | CN | claimed |
| CN-1659147-A | Pyridazine derivatives | MERCK PATENT GMBH (DE) | 2005-08-24 | — | — | CN | claimed |
| CN-1608067-A | Pyrrolopyrimidines as phosphodiesterase vii inhibitors | MERCK PATENT GMBH (DE) | 2005-04-20 | — | — | CN | claimed |
| WO-2005030149-A2 | SUPPRESSION OF HIV REPLICATION FOR PREVENTION AND TREATMENT OF HIV | THE JOHNS HOPKINS UNIVERSITY (US) | 2005-04-07 | — | — | WO | claimed |
| US-20040234499-A1 | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses | CENTOCOR, INC. | 2004-11-25 | — | — | US | claimed |
| CN-1489588-A | Thiazolyl-oxazolyl-pyrrolyl-and imidazolyl-acid amide derivatives useful as inbibitors of PDE 4 isozymes | �Ʒ� | 2004-04-14 | — | — | CN | claimed |
| US-20030235555-A1 | Asthma-related anti-IL-13 immunoglobulin derived proteins, compositions, methods and uses | CENTOCOR, INC. | 2003-12-25 | — | — | US | claimed |
| WO-2003086451-A1 | ASTHMA-RELATED ANTI-IL-13 IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES | CENTOCOR, INC. (US) | 2003-10-23 | — | — | WO | claimed |
| US-6320052-B1 | CRYSTALLINE PRECURSORS OF 1-(((1(R)-(3-(2-(7-CHLORO-2-QUINO LYNYL)ETHENYL)PHENYL)-3-(2-HYDROXY-1-METHYL-ETHYL)PHENYL) PROPYL)THIO)METHYL)CYCLOPROPYLACETIC ACID | MERCK & CO., INC. | 2001-11-20 | — | — | US | claimed |
| EP-0737186-B1 | PROCESS FOR THE PREPARATION OF LEUKOTRIENE ANTAGONISTS | MERCK & CO INC (US) | 1998-08-19 | — | — | EP | claimed |
| US-5565473-A | USEFUL AS ANTI-ASTHMATIC, ANTI-ALLERGIC, ANTI-INFLAMMATORY AND CYTOPROTECTIVE AGENTS; MONTELUKAST AND ITS SODIUM SALT | MERCK FROSST CANADA, INC. (CA) | 1996-10-15 | — | — | US | claimed |